XIAP and lymphoma: ASTX660, a non-peptidomimetic small molecule antagonist of cIAP1/2 and XIAP (X-linked inhibitor of apoptosis protein), is in phase 1/2 study for advanced solid tumors and lymphomas and phase 2 study for Peripheral and Cutaneous T-Cell Lymphoma (TCL) [105] (Table 2).